treos logo.jpg
Treos Bio Forms New Subsidiary to Develop a Preventive COVID-19 Peptide Vaccine
June 15, 2020 07:15 ET | Treos Bio Corp.
LONDON, June 15, 2020 (GLOBE NEWSWIRE) -- Treos Bio Limited, a clinical stage biopharma company developing targeted peptide cancer immunotherapies, today said that it has developed and successfully...
treos logo.jpg
Treos Bio Reports Positive Final Results of Phase I/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster Presentation
May 29, 2020 12:17 ET | Treos Bio Corp.
LONDON, May 29, 2020 (GLOBE NEWSWIRE) -- Treos Bio Limited, a clinical stage biopharma company developing precision peptide cancer immunotherapies, today presented positive final data from a Phase...
treos logo.jpg
Treos Bio Presents Positive Data on Its Off-the-Shelf Shared Antigen-Based Cancer Vaccine Against Microsatellite-stable metastatic colorectal cancer and Personalized Vaccines Against Three Metastatic cancers
November 07, 2019 07:00 ET | Treos Bio Corp.
LONDON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Treos Bio has developed a unique approach to create cancer vaccines by focusing not just on the vaccine targets but also on delivering antigen targets to...
treos logo.jpg
Treos Bio Reports Updated Positive Results from a Phase 1/2 Clinical Trial of Precision Cancer Vaccine Plus Maintenance Therapy in Patients with Metastatic Colorectal Cancer
September 26, 2019 05:15 ET | Treos Bio Corp.
LONDON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Treos Bio Limited, which is developing personal cancer vaccines combined with companion diagnostic devices, reported updated positive results on the second...
treos logo.jpg
Treos Bio Announces Positive Interim Results from a Phase 1/2 Clinical Trial of Precision Cancer Vaccine Plus Maintenance Therapy in Patients with Metastatic Colorectal Cancer
May 28, 2019 08:15 ET | Treos Bio Corp.
LONDON, May 28, 2019 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, precision cancer vaccines combined with companion diagnostic devices, reported...
treos logo.jpg
Investigators Dose First Patient in Phase 1 Study of Treos Bio’s PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer
May 14, 2018 08:15 ET | Treos Bio Corp.
SAN FRANCISCO and LONDON, May 14, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion...
treos logo.jpg
Treos Bio Announces Activation of U.S. Clinical Trial Site for Phase 1 Study of PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer
April 11, 2018 08:15 ET | Treos Bio Corp.
SAN FRANCISCO and LONDON, April 11, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion...
treos logo.jpg
Treos Bio Names Gábor Illés as Its Chief Financial Officer
April 03, 2018 08:15 ET | Treos Bio Corp.
SAN FRANCISCO and LONDON, April 03, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion...
Treos Bio Announces FDA Approval of IND of Its First PolyPEPI™ Precision Cancer Vaccine for Metastatic Colorectal Cancer
January 24, 2018 08:15 ET | Treos Bio Corp.
SAN FRANCISCO and LONDON, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion...
treos logo.jpg
Treos Bio Enters into Agreement with PPD to Manage First-in-Man Trial of Its Lead Therapeutic Cancer Vaccine Program
September 20, 2017 08:15 ET | Treos Bio Limited
SAN FRANCISCO, CA and LONDON, UNITED KINGDOM--(Marketwired - Sep 20, 2017) - Treos Bio Limited, which is developing precision peptide cancer vaccines coupled with companion diagnostics, today...